Genedata, a provider of advanced software solutions for biopharmaceutical and biotech research and development (R&D), announced the establishment of Genedata Limited as a new subsidiary in the U.K. The company is headed by Managing Director Kevin Teburi, a recognized expert in life science informatics. Creating the U.K. subsidiary reinforces Genedata's commitment to collaborate closely with its rapidly growing client base in the U.K., one of the most exciting biotech hubs in the world, in particular in the high-potential field of precision medicine. 

The U.K.'s strong heritage in biopharmaceutical research and development and its early leadership position in precision medicine made the U.K. the obvious choice for the next step in Genedata's global expansion strategy. Genedata has established a consultancy team that works closely with existing clients in the U.K. Having seen major growth in the number of partners in the U.K., Genedata expects new clients to add to this momentum in the very near future. The Genedata U.K. team is set up to support companies of all sizes across the length and breadth of the country, and is backed by the full resources of the global Genedata organization. Offering and supporting the full suite of Genedata enterprise software solutions, Genedata Limited is now perfectly poised to expand its role in the U.K. biopharma and biotech field. 

"I have been very pleased with the growth of Genedata's business in the United Kingdom over the last few years," commented Dr. Othmar Pfannes, CEO of Genedata. "This is the right time to make this major investment, demonstrating our confidence and belief in the future of the U.K., and fulfilling our commitment to work with our clients as closely as possible. Now that we are established in the heart of one of the most important biopharmaceutical and biotech hubs in the world, we are perfectly positioned to continue our growth trajectory and bring great value to many of the world's leading research-based organizations."